Eledon Pharmaceuticals, Inc. (ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression Transcript

Group 1 - Eledon presented Phase II BESTOW data, highlighting the progress in their development of tegoprubart [2][3] - The call included key executives from Eledon, including the CEO, President, CFO, CMO, and Chief Regulatory Officer, indicating a strong leadership presence [2] - Dr. Andrew Adams, a notable figure in transplantation, participated in the presentation, suggesting the significance of the data shared [2]